CN109562164B - 使用双特异性抗体消除患者中的造血干细胞/造血祖细胞(hsc/hp)的方法 - Google Patents

使用双特异性抗体消除患者中的造血干细胞/造血祖细胞(hsc/hp)的方法 Download PDF

Info

Publication number
CN109562164B
CN109562164B CN201780034711.2A CN201780034711A CN109562164B CN 109562164 B CN109562164 B CN 109562164B CN 201780034711 A CN201780034711 A CN 201780034711A CN 109562164 B CN109562164 B CN 109562164B
Authority
CN
China
Prior art keywords
cells
cell
ser
flt3
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780034711.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109562164A (zh
Inventor
V.桑德勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heimer Zhenke Pharmaceutical Co ltd
Original Assignee
Heimer Zhenke Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heimer Zhenke Pharmaceutical Co ltd filed Critical Heimer Zhenke Pharmaceutical Co ltd
Publication of CN109562164A publication Critical patent/CN109562164A/zh
Application granted granted Critical
Publication of CN109562164B publication Critical patent/CN109562164B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201780034711.2A 2016-04-04 2017-04-04 使用双特异性抗体消除患者中的造血干细胞/造血祖细胞(hsc/hp)的方法 Active CN109562164B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317906P 2016-04-04 2016-04-04
US62/317906 2016-04-04
PCT/US2017/025951 WO2017176760A2 (en) 2016-04-04 2017-04-04 Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies

Publications (2)

Publication Number Publication Date
CN109562164A CN109562164A (zh) 2019-04-02
CN109562164B true CN109562164B (zh) 2022-10-04

Family

ID=60001426

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780034711.2A Active CN109562164B (zh) 2016-04-04 2017-04-04 使用双特异性抗体消除患者中的造血干细胞/造血祖细胞(hsc/hp)的方法

Country Status (6)

Country Link
US (2) US11021536B2 (https=)
EP (1) EP3439699A4 (https=)
JP (1) JP2019513836A (https=)
CN (1) CN109562164B (https=)
CA (1) CA3019581A1 (https=)
WO (1) WO2017176760A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3105252T3 (da) * 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
US11104738B2 (en) 2016-04-04 2021-08-31 Hemogenyx Pharmaceuticals Llc Monoclonal antibodies to human FLT3/FLK2 receptor protein
WO2017176760A2 (en) 2016-04-04 2017-10-12 Vladislav Sandler Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
EP3623383A1 (en) * 2018-09-11 2020-03-18 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved bispecific flt3xcd3 antigen binding proteins
CN113056486B (zh) 2018-09-11 2025-06-17 德国肿瘤研究中心 改善的抗flt3抗原结合蛋白
JP7642542B2 (ja) 2018-12-18 2025-03-10 ベーリンガー・インゲルハイム・イオ・カナダ・インコーポレイテッド Ｆｌｔ３アゴニスト抗体及びその使用
EP3962527A4 (en) 2019-04-30 2023-11-01 Senti Biosciences, Inc. CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
WO2021007266A1 (en) * 2019-07-09 2021-01-14 Hemogenyx Llc Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
WO2023023491A1 (en) 2021-08-16 2023-02-23 Hemogenyx Pharmaceuticals Llc Anti-flt3 antibodies, cars, car t cells and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102770453A (zh) * 2009-12-23 2012-11-07 合成免疫股份有限公司 抗flt3抗体及其使用方法
CN104203981A (zh) * 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
ES2869972T3 (es) 2015-01-26 2021-10-26 Cellectis Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
WO2016172026A1 (en) 2015-04-20 2016-10-27 The Board Of Regents Of The University Of Texas System Clec11a is a bone growth agent
US11104738B2 (en) 2016-04-04 2021-08-31 Hemogenyx Pharmaceuticals Llc Monoclonal antibodies to human FLT3/FLK2 receptor protein
WO2017176760A2 (en) 2016-04-04 2017-10-12 Vladislav Sandler Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
CN109641051A (zh) 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
EP3612568B8 (en) 2017-04-18 2021-12-08 Autolus Limited Cell

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102770453A (zh) * 2009-12-23 2012-11-07 合成免疫股份有限公司 抗flt3抗体及其使用方法
CN104203981A (zh) * 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia;Michael Durben等;《Molecular Therapy》;20150203;第23卷(第4期);图1和、摘要和第654页左栏第4-5段和右栏第1段 *
Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia;M Hofmann等;《Leukemia》;20120106;第26卷;第1228-1237页 *

Also Published As

Publication number Publication date
EP3439699A4 (en) 2019-11-20
WO2017176760A2 (en) 2017-10-12
CN109562164A (zh) 2019-04-02
US11945866B2 (en) 2024-04-02
US20190127464A1 (en) 2019-05-02
US11021536B2 (en) 2021-06-01
JP2019513836A (ja) 2019-05-30
CA3019581A1 (en) 2017-10-12
WO2017176760A3 (en) 2017-11-16
EP3439699A2 (en) 2019-02-13
US20210188978A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
CN109562164B (zh) 使用双特异性抗体消除患者中的造血干细胞/造血祖细胞(hsc/hp)的方法
CN113543799B (zh) 靶向dll3的嵌合抗原受体和结合剂
TWI842703B (zh) Dll3 的嵌合受體及其使用方法
AU2020384369B2 (en) Anti-TCR antibody molecules and uses thereof
DK1648507T3 (en) PROCEDURES AND COMPOSITIONS FOR INCREASING THE EFFECTIVENESS OF THERAPEUTIC ANTIBODIES USING COMPOUNDS THAT POTENTATE NK CELLS
JP2019516352A (ja) Ｆｌｔ３に対するキメラ受容体及びその使用方法
US11104738B2 (en) Monoclonal antibodies to human FLT3/FLK2 receptor protein
JP2006528627A (ja) アロ反応性ナチュラルキラー細胞を使用する治療用抗体の有効性を増加するための方法および組成物
US20230218669A1 (en) Augmenting antigen-negative cell death in antigen-targeted immunotherapies
CN114829399A (zh) 使用双特异性抗体消除患者中的造血干细胞/造血祖细胞(hsc/hp)的方法
EP4378953A1 (en) Cd229 targeting moiety for the tratment of cd229 positive cancer
CN118284621A (zh) 抗flt3抗体、car、car t细胞和使用方法
CA3229520A1 (en) Bispecific anti-flt3/cd3 antibodies and methods of use
US20240216432A1 (en) Anti-flt3 antibodies, cars, car t cells and methods of use
US20240350630A1 (en) Compositions and methods of treating disease with chimeric antigen receptors to b cell maturation antigen (bcma)
JP7692214B2 (ja) 抗体
HK40063038B (zh) 靶向dll3的嵌合抗原受体和结合剂
EA044866B1 (ru) Химерные рецепторы к flt3 и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: New York State, USA

Applicant after: Heimer Zhenke Pharmaceutical Co.,Ltd.

Address before: New York State, USA

Applicant before: HEMOGENYX LLC

GR01 Patent grant
GR01 Patent grant